Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
1.1 Billion Yen for Revenue Guarantee System for Antibiotics: FY2023 Budget
The Ministry of Health, Labor and Welfare (MHLW) is set to roll out a revenue-guarantee system on a pilot basis in FY2023 as a pull incentive for drug makers to develop antibiotics countering antimicrobial resistance (AMR). The MHLW’s Health Service…
To read the full story
Related Article
REGULATORY
- Novo’s Wegovy Nears Japan Approval as First MASH Therapy
June 1, 2026
- Japan Enacts Reform Bill Paving Way for OTC-Like Drug Charges
June 1, 2026
- Four Pharma Secondees Join AMED Drug Discovery Initiative
June 1, 2026
- Finance Minister Backs Further Debate on Low-Risk Medicines: CEFP Minutes
May 29, 2026
- LDP HQ Finalizes Recommendations ahead of Growth Strategy
May 29, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…